Ipsen Pharma conducted a buy-back program from June 15 to June 19, 2026, purchasing a total of 28,105 of its own shares. The daily average purchase price ranged around €155 to €157 per share on the Euronext Paris market. This buy-back is part of Ipsen's ongoing strategy to manage its capital and potentially support its stock price. Investors should watch for further updates on the program and its impact on Ipsen's share value and capital structure.
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
Glider has introduced a global investing platform for tokenized stocks that operates permissionlessly, bypassing the SEC's Tokenized Securities Venues (TSVs) which 50 public companies recently rejected. Backed by major investors like a16z and Coinbas...
Tilray Brands announced that its subsidiaries 10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing are now the official craft beer partners of the Portland Trail Blazers. This partnership expands the availability of Oregon craft beers a...
Nexpu Ltd.'s subsidiary, Top Kingwin Hi Tech Inc., has finished delivering all 10,000 TK-D2C robots to Walkers Times International under a $4.8 million resale contract signed in 2025. The deliveries were completed in batches, with the final 5,000 uni...
